Total Voting Rights

RNS Number : 8707U

Allergy Therapeutics PLC

01 July 2009

 



Wednesday 1 July 2009

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

Appointment of Directors, Directors Holdings and Total Voting Rights

AIM Rule Disclosure- Schedule 2(g)

Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, announces that further to the announcement made by the Company on 12 June 2009, Alejandro Esteban Weinstein Manieu (51) and Manuel Llobet (45) were today appointed as directors of the Company.

In accordance with Rule 17 of the AIM Rules, the following information can be disclosed regarding Alejandro Weinstein and Manuel Llobet:

Alejandro Weinstein

Current directorships and partnerships	Past directorships and partnerships within the last five years
Genomika Foundation
Laboratorios Recalcine S.A.
Biomedical Research Consortium

Manuel Llobet

Current directorships and partnerships	Past directorships and partnerships within the last five years
	Drokasa Peru S.A.
	Gynopharm S.A. (Costa Rica)
	Gynopharm S.A. (Colombia)
	Laboratorios Elea México S.A. de C.V.
	Servicios Elche S.A. de C.V.
	Laboratorios Atlas
	Gynopharm de Venezuela C.A.
	Farmindustria S.A.

There is no further information to be disclosed under Schedule 2(g) of the AIM Rules for Companies.

Directors' holdings

After Admission, the interests of the Directors and the percentage of the Company's issued share capital which they represent are as follows:

	Number of Ordinary Shares	% of Share Capital after Admission
Keith I Carter	3,192,669	1.21%
Ignace R Goethals	4,897,912	1.86%
Ian Postlethwaite	0	0.00%
Tom Holdich	0	0.00%
Christian Gratz	510,658	0.19%
Stephen R Smith	756,513	0.29%
Virinder Nohria	5,211	0.00%
Alejandro Weinstein*	0	0.00%
Manuel Llobet**	0	0.00%

*Alejandro Weinstein is a beneficiary of Azure Ventures Limited, which is interested in 104,166,666 shares, 39.46% of the Company

** Manuel Llobet is a beneficiary of Wild Indigo S.A, which is interested in 3,125,000 shares, 1.18% of the Company

Total Voting Rights Following Admission

The Company's issued voting share capital is 263,998,551 ordinary shares of 0.1p each.

For further information

Allergy Therapeutics	[phone]
Keith Carter, Chief Executive
www.allergytherapeutics.com
Nomura Code Securities	[phone]
Juliet Thompson/ Clare Terlouw
Financial Dynamics	[phone]
Ben Brewerton/ Susan Quigley

 

END

 

 

TVREAKXFEDSNEEE